- Report
- March 2024
- 191 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- March 2024
- 196 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- June 2023
- 103 Pages
Global
From €5752EUR$5,950USD£4,941GBP
- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- July 2023
- 115 Pages
Global
From €3722EUR$3,850USD£3,197GBP
- Report
- April 2024
- 93 Pages
Global
From €5414EUR$5,600USD£4,650GBP
- Report
- April 2024
- 137 Pages
Global
From €3770EUR$3,899USD£3,238GBP
- Report
- February 2024
- 117 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- February 2024
- 125 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2900EUR$3,000USD£2,491GBP
- Report
- August 2023
- 255 Pages
Global
From €9185EUR$9,500USD£7,889GBP
- Report
- April 2024
- 180 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- November 2023
- 180 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- November 2023
- 180 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- January 2021
- 420 Pages
United States
From €2707EUR$2,800USD£2,325GBP
- Report
- October 2022
- 200 Pages
Global
From €2320EUR$2,400USD£1,993GBP
- Report
- December 2022
- 196 Pages
Global
From €4760EUR$5,095USD£3,950GBP
- Report
- February 2023
- 244 Pages
Global
From €4061EUR$4,200USD£3,488GBP
- Report
- January 2023
- 125 Pages
Global
From €2407EUR$2,490USD£2,068GBP
- Report
- June 2020
- 163 Pages
Global
From €4012EUR$4,150USD£3,446GBP
Rivastigmine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is a cholinesterase inhibitor, meaning it works by increasing the amount of a chemical messenger in the brain that helps nerve cells communicate with each other. It is used to treat mild to moderate dementia caused by Alzheimer's disease or Parkinson's disease. It is also used to treat mild to moderate dementia caused by Lewy body dementia. Rivastigmine is available in both capsule and patch form.
Rivastigmine is part of the Central Nervous System (CNS) drugs market, which includes drugs used to treat neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. CNS drugs are used to treat a wide range of conditions, from mild to severe. The CNS drugs market is highly competitive, with many companies offering similar products.
Some companies in the Rivastigmine market include Novartis, Pfizer, Mylan, and Teva Pharmaceuticals. Show Less Read more